The agency replaces ten year incumbent Athena Medical PR, which failed to retain the business after repitching for the account.
Ogilvy will handle the UK and European PR for IDIS, which helps patients suffering from a variety of serious conditions to gain access to medicines in the pre-approval phase. Certain patients are able to use unapproved drugs through named patient programmes.
The agency will work with IDIS to deliver a comms campaign to showcase IDIS ' corporate
offering and highlight the benefits of named patient programmes as part of a successful
market access strategy.
IDIS works closely with the biotech and pharma industry, pharmacists, physicians and
medical authorities to supply medicines in the pre-approval and pre-launch phase in an
ethical and responsible way.
Ogilvy Healthworld UK will develop a comms campaign to engage these key audiences and help to bring named patient programmes to the centre of global market access planning and product life cycle management. ‘Supporting patients with unmet medical needs is at the
heart of everything we do,' said IDIS marketing director Andrew Moody. ‘We want to
shape current market access strategies and demonstrate how the IDIS service offering
can optimise life cycle management.'
Moody joined IDIS in September 2008 and is charged with overseeing the firm's global marketing functions. The appointment will support the company's rebranding later this year.